Posted by Michael Wonder on 23 Jul 2025
Bavarian Nordic receives acceptance from Health Canada for review of the new drug submission for its chikungunya vaccine
22 July 2025 - Bavarian Nordic announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunisation to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.
The application screening acceptance by the Directorate confirms that the new drug submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.
